Cost per responder analysis of guselkumab versus targeted therapies in the treatment of moderate to severe plaque psoriasis in Germany

TY - JOUR

T1 - Cost per responder analysis of guselkumab versus targeted therapies in the treatment of moderate to severe plaque psoriasis in Germany

AU - Augustin, Matthias

AU - Wirth, Daniel

AU - Mahlich, Jörg

AU - Pepper, Alicia N

AU - Druchok, Cheryl

PY - 2022/3

Y1 - 2022/3

N2 - BACKGROUND: The fully human monoclonal antibody guselkumab is an effective treatment option for patients with moderate to severe psoriasis.OBJECTIVE: The objective of this study was to examine the cost per responder of guselkumab compared with other targeted therapies for the treatment of moderate to severe plaque psoriasis in Germany.METHODS: A one-year cost per responder model was developed based on efficacy and safety data from a published network meta-analysis. Drug, treatment administration, resource use, and adverse event costs were included in the analysis. The primary analysis assessed the cost per Psoriasis Area and Severity Index (PASI) 90 responder at week 16. Additional analyses were conducted at year 1. In the year 1 analyses, treatment response was assessed at the end of the induction period (week 16) to determine which patients continued onto maintenance therapy (responders) and which patients moved onto a subsequent adalimumab or secukinumab therapy (non-responders).RESULTS: At week 16, the cost per PASI 90 responder was lower for guselkumab than all comparators except adalimumab and brodalumab. Similarly, in the year 1 analyses, guselkumab had a lower cost per PASI 90 responder than all comparators except brodalumab.CONCLUSIONS: Guselkumab is a cost-effective therapy option in Germany.

AB - BACKGROUND: The fully human monoclonal antibody guselkumab is an effective treatment option for patients with moderate to severe psoriasis.OBJECTIVE: The objective of this study was to examine the cost per responder of guselkumab compared with other targeted therapies for the treatment of moderate to severe plaque psoriasis in Germany.METHODS: A one-year cost per responder model was developed based on efficacy and safety data from a published network meta-analysis. Drug, treatment administration, resource use, and adverse event costs were included in the analysis. The primary analysis assessed the cost per Psoriasis Area and Severity Index (PASI) 90 responder at week 16. Additional analyses were conducted at year 1. In the year 1 analyses, treatment response was assessed at the end of the induction period (week 16) to determine which patients continued onto maintenance therapy (responders) and which patients moved onto a subsequent adalimumab or secukinumab therapy (non-responders).RESULTS: At week 16, the cost per PASI 90 responder was lower for guselkumab than all comparators except adalimumab and brodalumab. Similarly, in the year 1 analyses, guselkumab had a lower cost per PASI 90 responder than all comparators except brodalumab.CONCLUSIONS: Guselkumab is a cost-effective therapy option in Germany.

KW - Adalimumab/therapeutic use

KW - Antibodies, Monoclonal/therapeutic use

KW - Antibodies, Monoclonal, Humanized

KW - Humans

KW - Psoriasis/chemically induced

KW - Severity of Illness Index

KW - Treatment Outcome

U2 - 10.1080/09546634.2020.1793891

DO - 10.1080/09546634.2020.1793891

M3 - SCORING: Journal article

C2 - 32663067

VL - 33

SP - 976

EP - 982

JO - J DERMATOL TREAT

JF - J DERMATOL TREAT

SN - 0954-6634

IS - 2

ER -